Selected publications
-
Prostate cancer-Associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Nature Medicine.
2017
Academic Article
GET IT
Times cited: 11 -
Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis.
Journal of Experimental Medicine.
2015
Academic Article
GET IT
Times cited: 27 -
BET protein antagonist JQ1 is synergistically lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.
Molecular Cancer Therapeutics.
2014
Academic Article
GET IT
Times cited: 58 -
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.
Blood.
2014
Academic Article
GET IT
Times cited: 46 -
Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia.
Journal of Clinical Investigation.
2014
Academic Article
GET IT
Times cited: 65 -
An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.
Nature Genetics.
2014
Academic Article
GET IT
Times cited: 117 -
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.
Journal of Experimental Medicine.
2012
Academic Article
GET IT
Times cited: 96 -
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.
Journal of Clinical Investigation.
2010
Academic Article
GET IT
Times cited: 111 -
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Science.
2007
Academic Article
GET IT
Times cited: 643 -
SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.
Clinical Cancer Research.
2006
Academic Article
GET IT
Times cited: 54 -
Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.
Cancer Research.
1999
Academic Article
GET IT
Times cited: 124